VestGen Advisors
VRTX icon

VestGen Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

VestGen Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.55M Buy
4,870
+2,671
+121% +$1.37M 0.08% 237
2026
Q2 		$1.09M Sell
2,199
-73
-3% -$32.4K 0.03% 439
2026
Q1 		$1.02M Buy
2,272
+245
+12% +$114K 0.03% 457
2025
Q4 		$919K Sell
2,027
-519
-20% -$224K 0.04% 373
2025
Q3 		$997K Sell
2,546
-515
-17% -$215K 0.03% 369
2025
Q2 		$1.36M Sell
3,061
-202
-6% -$93.1K 0.05% 276
2025
Q1 		$1.58M Buy
+3,263
New +$1.52M 0.07% 237

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

VestGen Advisors's VRTX Position: Q3 2026 in Review

VestGen Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 121% in Q3 2026, buying an estimated $1.37M and bringing the position to 4,870 shares worth $2.55M. The position accounts for 0.08% of the portfolio, ranked #237.

VestGen Advisors first reported a position in VRTX in Q1 2025 and has held it in 7 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • VestGen Advisors held 4,870 shares of Vertex Pharmaceuticals worth $2.55M as of Q3 2026.
  • VestGen Advisors bought 2,671 Vertex Pharmaceuticals shares in Q3 2026, an estimated $1.37M.
  • Vertex Pharmaceuticals made up 0.08% of VestGen Advisors's portfolio in Q3 2026, its #237 holding.
  • VestGen Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on VestGen Advisors's 13F filing for Q3 2026, filed 27 Oct 2026.